2026 Q3 -tulosraportti
45 päivää sitten
‧27 min
12,8007 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 22.5. | ||
2026 Q2 -tulosraportti 13.2. | ||
2026 Q1 -tulosraportti 14.11.2025 | ||
2025 Q4 -tulosraportti 28.8.2025 | ||
2025 Q3 -tulosraportti 22.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 min sittenHamlet BioPharma Alpha 1H Phase III study has been on EU Clinical Trials for some time now. A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer See tab "Trial Documents" for the protocol. Randomization: Approx. 194 patients will be randomized 1:1 to Alpha1H vs Standard of Care (no neo-adjuvant treatment) https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2026-525531-16-00
·3 t sittensome are probably pre-subscribed! from the start 5.5 million! turnover today so far 206,000!! Nah, I don't think so!
·23.6.Hello again Aborum. Since you mentioned UroGen, they do have a finished treatment for the same patient group as Hamlet. https://www.targetedonc.com/view/fda-approves-intravesical-mitomycin-in-non-muscle-invasive-bladder-cancer UroGen has Zusduri which has crossed the finish line. With 80% CRR in its phase 3 study with 240 patients. What result do you envision Hamlet will achieve, and will they have a similar number of patients in their phase 3 study? Do you agree that it is a direct competitor to Hamlet? If not, why?
24.6.Zusduri has much worse safety profile. Alpha1H is first-in-class. Bladder cancer is just the beginning. When the German company signed the letter of intent, they knew about Zusduri. Still, they wanted to sign.
·18.6. · MuokattuValuation, insider selling, and development pace are often discussed at Hamlet BioPharma. But it can also be relevant to look at the factors that can potentially drive value creation forward. Hamlet BioPharma is now entering Phase 3 with Alpha1H after achieving Fast Track status from the FDA and with support from internationally recognized KOLs in urology. At the same time, a production platform, GMP processes, and CMC documentation have been established, which are normally both time- and capital-intensive milestones for a biotech company. The clinical data published by the company to date show a complete response rate (CR) of 88%, approximately 66% tumor reduction, and a safety profile without reported toxicity. In addition, there are observations indicating that the treatment can be repeated without the development of resistance. ”the NMIBC market is expected to grow from USD 2.6 billion in 2023 to an estimated USD 21.1 billion by 2034, at a compound annual growth rate (CAGR) of 21.4%. .. Alpha1H, with its promising clinical results and immune activation profile, is uniquely suited to address the need for novel NMIBC treatment.” Within NMIBC, there are currently no approved neoadjuvant treatments before TURBT; surgery therefore remains the standard treatment. If Alpha1H can confirm its results in Phase 3, the company could potentially establish a completely new treatment offering in a very large patient segment with a significant "unmet medical need" (hence FDA's Fast Track designation). At the same time, Hamlet BioPharma is currently trading at a market capitalization of under 1.5 billion SEK, which is significantly lower than several comparable companies in the bladder cancer area, such as CG Oncology and UroGen. Naturally, the companies are not directly comparable, but the difference in valuation is significant and worth discussing. According to the latest update, Prague is being initiated as the first Phase 3 site, and more sites are expected to follow. In addition, the market is awaiting the final Phase 3 protocol and further news regarding the ongoing partner negotiations, which the company continues to report are progressing as planned. Regarding the previous insider selling, a limited 80,000 shares have been sold out of a position of 2.4 million shares, and considering participation in the directed issue, the logical explanation is that the capital covers participation in TO5B which runs until the end of July, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
45 päivää sitten
‧27 min
12,8007 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 min sittenHamlet BioPharma Alpha 1H Phase III study has been on EU Clinical Trials for some time now. A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer See tab "Trial Documents" for the protocol. Randomization: Approx. 194 patients will be randomized 1:1 to Alpha1H vs Standard of Care (no neo-adjuvant treatment) https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2026-525531-16-00
- ·3 t sittensome are probably pre-subscribed! from the start 5.5 million! turnover today so far 206,000!! Nah, I don't think so!
- ·23.6.Hello again Aborum. Since you mentioned UroGen, they do have a finished treatment for the same patient group as Hamlet. https://www.targetedonc.com/view/fda-approves-intravesical-mitomycin-in-non-muscle-invasive-bladder-cancer UroGen has Zusduri which has crossed the finish line. With 80% CRR in its phase 3 study with 240 patients. What result do you envision Hamlet will achieve, and will they have a similar number of patients in their phase 3 study? Do you agree that it is a direct competitor to Hamlet? If not, why?24.6.Zusduri has much worse safety profile. Alpha1H is first-in-class. Bladder cancer is just the beginning. When the German company signed the letter of intent, they knew about Zusduri. Still, they wanted to sign.
- ·18.6. · MuokattuValuation, insider selling, and development pace are often discussed at Hamlet BioPharma. But it can also be relevant to look at the factors that can potentially drive value creation forward. Hamlet BioPharma is now entering Phase 3 with Alpha1H after achieving Fast Track status from the FDA and with support from internationally recognized KOLs in urology. At the same time, a production platform, GMP processes, and CMC documentation have been established, which are normally both time- and capital-intensive milestones for a biotech company. The clinical data published by the company to date show a complete response rate (CR) of 88%, approximately 66% tumor reduction, and a safety profile without reported toxicity. In addition, there are observations indicating that the treatment can be repeated without the development of resistance. ”the NMIBC market is expected to grow from USD 2.6 billion in 2023 to an estimated USD 21.1 billion by 2034, at a compound annual growth rate (CAGR) of 21.4%. .. Alpha1H, with its promising clinical results and immune activation profile, is uniquely suited to address the need for novel NMIBC treatment.” Within NMIBC, there are currently no approved neoadjuvant treatments before TURBT; surgery therefore remains the standard treatment. If Alpha1H can confirm its results in Phase 3, the company could potentially establish a completely new treatment offering in a very large patient segment with a significant "unmet medical need" (hence FDA's Fast Track designation). At the same time, Hamlet BioPharma is currently trading at a market capitalization of under 1.5 billion SEK, which is significantly lower than several comparable companies in the bladder cancer area, such as CG Oncology and UroGen. Naturally, the companies are not directly comparable, but the difference in valuation is significant and worth discussing. According to the latest update, Prague is being initiated as the first Phase 3 site, and more sites are expected to follow. In addition, the market is awaiting the final Phase 3 protocol and further news regarding the ongoing partner negotiations, which the company continues to report are progressing as planned. Regarding the previous insider selling, a limited 80,000 shares have been sold out of a position of 2.4 million shares, and considering participation in the directed issue, the logical explanation is that the capital covers participation in TO5B which runs until the end of July, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 22.5. | ||
2026 Q2 -tulosraportti 13.2. | ||
2026 Q1 -tulosraportti 14.11.2025 | ||
2025 Q4 -tulosraportti 28.8.2025 | ||
2025 Q3 -tulosraportti 22.5.2025 |
2026 Q3 -tulosraportti
45 päivää sitten
‧27 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 22.5. | ||
2026 Q2 -tulosraportti 13.2. | ||
2026 Q1 -tulosraportti 14.11.2025 | ||
2025 Q4 -tulosraportti 28.8.2025 | ||
2025 Q3 -tulosraportti 22.5.2025 |
12,8007 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 min sittenHamlet BioPharma Alpha 1H Phase III study has been on EU Clinical Trials for some time now. A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer See tab "Trial Documents" for the protocol. Randomization: Approx. 194 patients will be randomized 1:1 to Alpha1H vs Standard of Care (no neo-adjuvant treatment) https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2026-525531-16-00
- ·3 t sittensome are probably pre-subscribed! from the start 5.5 million! turnover today so far 206,000!! Nah, I don't think so!
- ·23.6.Hello again Aborum. Since you mentioned UroGen, they do have a finished treatment for the same patient group as Hamlet. https://www.targetedonc.com/view/fda-approves-intravesical-mitomycin-in-non-muscle-invasive-bladder-cancer UroGen has Zusduri which has crossed the finish line. With 80% CRR in its phase 3 study with 240 patients. What result do you envision Hamlet will achieve, and will they have a similar number of patients in their phase 3 study? Do you agree that it is a direct competitor to Hamlet? If not, why?24.6.Zusduri has much worse safety profile. Alpha1H is first-in-class. Bladder cancer is just the beginning. When the German company signed the letter of intent, they knew about Zusduri. Still, they wanted to sign.
- ·18.6. · MuokattuValuation, insider selling, and development pace are often discussed at Hamlet BioPharma. But it can also be relevant to look at the factors that can potentially drive value creation forward. Hamlet BioPharma is now entering Phase 3 with Alpha1H after achieving Fast Track status from the FDA and with support from internationally recognized KOLs in urology. At the same time, a production platform, GMP processes, and CMC documentation have been established, which are normally both time- and capital-intensive milestones for a biotech company. The clinical data published by the company to date show a complete response rate (CR) of 88%, approximately 66% tumor reduction, and a safety profile without reported toxicity. In addition, there are observations indicating that the treatment can be repeated without the development of resistance. ”the NMIBC market is expected to grow from USD 2.6 billion in 2023 to an estimated USD 21.1 billion by 2034, at a compound annual growth rate (CAGR) of 21.4%. .. Alpha1H, with its promising clinical results and immune activation profile, is uniquely suited to address the need for novel NMIBC treatment.” Within NMIBC, there are currently no approved neoadjuvant treatments before TURBT; surgery therefore remains the standard treatment. If Alpha1H can confirm its results in Phase 3, the company could potentially establish a completely new treatment offering in a very large patient segment with a significant "unmet medical need" (hence FDA's Fast Track designation). At the same time, Hamlet BioPharma is currently trading at a market capitalization of under 1.5 billion SEK, which is significantly lower than several comparable companies in the bladder cancer area, such as CG Oncology and UroGen. Naturally, the companies are not directly comparable, but the difference in valuation is significant and worth discussing. According to the latest update, Prague is being initiated as the first Phase 3 site, and more sites are expected to follow. In addition, the market is awaiting the final Phase 3 protocol and further news regarding the ongoing partner negotiations, which the company continues to report are progressing as planned. Regarding the previous insider selling, a limited 80,000 shares have been sold out of a position of 2.4 million shares, and considering participation in the directed issue, the logical explanation is that the capital covers participation in TO5B which runs until the end of July, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt